CLINACIN 25 MG TABLETS

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Active ingredient:

CLINDAMYCIN (AS CLINDAMYCIN HYDROCHLORIDE)

Available from:

Chanelle Animal Health Ltd.

ATC code:

QJ01FF01

INN (International Name):

CLINDAMYCIN (AS CLINDAMYCIN HYDROCHLORIDE)

Dosage:

25 mg/tablet

Pharmaceutical form:

Tablets

Prescription type:

POM

Therapeutic group:

Canine, Feline

Therapeutic area:

Clindamycin

Therapeutic indications:

Antibacterial

Authorization status:

Authorised

Authorization date:

1999-10-29

Summary of Product characteristics

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Clinacin 25 mg Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
Clindamycin 25 mg
(as Clindamycin hydrochloride)
For a full list of excipients see section 6.1.
3 PHARMACEUTICAL FORM
Tablet.
A small round white tablet with a break-line on one side and the letter J embossed on both sides of the breakline. The
tablets can be divided into equal halves.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs and Cats.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Clinacin 25 mg Tablets are antibiotics indicated for the treatment of infected wounds, abscesses, pyoderma and oral
cavity/dental infections caused by or associated with clindamycin-sensitive staphylococci, streptococci, bacteroidaceae,
_Fusobacterium necrophorum, Clostridium perfringens _and osteomyelitis caused by _Staphylococcus aureus. _Clinacin 25
mg Tablets can also be used to help provide antimicrobial cover during dental procedures.
4.3 CONTRAINDICATIONS
Do not use in case of hypersensitivity to clindamycin or lincomycin.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
HEALTH PRODUCTS REGULATORY AUTHORITY
________________________________________________________________________________________________________________________
_Date Printed 10/11/2016_
_CRN 7024870_
_page number: 1_
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
During prolonged osteomyelitis therapy of one month or greater, periodic liver and kidney function tests and blood counts
should be performed. Patients with severe renal and/or very severe hepatic disturbances accompanied by severe metabolic
aberrations should be dosed with caution and should be monitored by serum examination during high dose clindamycin
therapy.
The product should not be used in cats